Heart Rate at Baseline Influences the Effect of Ivabradine on Cardiovascular Outcomes in Chronic Heart Failure: Analysis from the SHIFT Study
In SHIFT (Systolic heart failure treatment with the If inhibitor ivabradine trial), heart rate reduction with the If inhibitor ivabradine significantly reduced major cardiovascular outcomes in HF patients in sinus rhythm with heart rate ≥70 bpm.